Oxandrolone

Plastic and Reconstructive Surgery

Volumn 118, Issue 3, 2006, Pages 791-794

  Akyurek, Mustafa ^a   Dunn, Raymond M ^a  

^a University of Massachusetts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMINOTRANSFERASE; ANABOLIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OXANDROLONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ADENOMA; ALCOHOL LIVER DISEASE; ALOPECIA; ARTICLE; BODY COMPOSITION; BURN; CATABOLISM; CHRONIC DISEASE; CLINICAL TRIAL; CLITORIS; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; HAIR GROWTH; HUMAN; LARYNX DISORDER; LIBIDO DISORDER; LIVER CELL CARCINOMA; LIVER INJURY; LIVER TOXICITY; MUSCLE ATROPHY; NEUROMUSCULAR DISEASE; OBSTRUCTIVE JAUNDICE; PELIOSIS HEPATIS; PRIORITY JOURNAL; PROTEIN INTAKE; SHORT STATURE; SIDE EFFECT; TURNER SYNDROME; WEIGHT REDUCTION;

ADULT; ANABOLIC AGENTS; APPETITE; CHILD; FEMALE; HUMANS; MALE; OXANDROLONE; RANDOMIZED CONTROLLED TRIALS; VIRILISM; WASTING SYNDROME; WEIGHT GAIN;

EID: 33748253474     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.prs.0000233034.29726.c9     Document Type: Article

References (29)

1. Basaria, S., Wahlstrom, J. T., and Dobs, A. S. Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J. Clin. Endocrinol. Metab. 86: 5108, 2001.
2. Orr, R., and Singh, M. F. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders. Drugs 64: 725, 2004.
3. Fox, M., Minot, A. S., and Liddle, G. W. Oxandrolone: A potent anabolic steroid of novel chemical configuration. J. Clin. Endocrinol. Metab. 22: 921, 1962.
4. Bahrke, M. S., and Yesalis, C. E. Abuse of anabolic androgenic steroids and related substances in sports and exercise. Curr. Opin. Pharmacol. 4: 614, 2004.
5. Brown, G. A., Vukovich, M. D., Sharp, R. L., Reifenrath, T. A., Parsons, K. A., and King, D. S. Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men. J. Appl. Physiol. 87: 2274, 1999.
6. Demling, R. H., and DeSanti, L. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J. Trauma 43: 47, 1997.
7. Gervasio, J. M., Dickerson, R. N., Swearingen, J., et al. Oxandrolone in trauma patients. Pharmacotherapy 20: 1328, 2000.
8. Wolf, S. E., Thomas, S. J., Dasu, M. R., et al. Improved net protein balance, lean mass, and gene expression changes with oxandrolone treatment in the severely burned. Ann. Surg. 237: 801, 2003.
9. Karim, A., Ranney, R., Zagarella, J., et al. Oxandrolone disposition and metabolism in man. Clin. Pharmacol. Ther. 14: 862, 1973.
10. Harrison, L., Martin, D., Gotlin, R., et al. Effect of extended use of single anabolic steroids on urinary steroid excretion and metabolism. J. Chromatogr. 489: 121, 1989.
11. Bi, H., and Masse, R. Studies on anabolic steroids. J. Steroid Biochem. Mol. Biol. 42: 533, 1992.
12. Albanese, A., Lorenze, E., and Orto, L. Nutritional and metabolic effects of some newer steroids. N.Y. State J. Med. 62: 1607, 1962.
13. Jackson, S., Rallison, M., Buntin, W., et al. Use of oxandrolone for growth stimulation in children. Am. J. Dis. Child. 126: 481, 1973.
14. Langer, C. J., Hoffman, J. P., and Ottery, F. D. Clinical significance of weight loss in cancer patients: Rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition 17: 1, 2001.
15. Berger, J. R., Pall, L., Hall, C. D., et al. Oxandrolone in AIDS-wasting myopathy. AIDS 10: 1657, 1996.
16. Stahnke, N., Keller, E., and Landy, H. Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. J. Pediatr. Endocrinol. Metab. 15: 129, 2002.
17. Murphy, K. D., Suchmor, T., Mlcak, R. P., et al. Effects of long-term oxandrolone administration in severely burned children. Surgery 136: 219, 2004.
18. Church, J. A. Oxandrolone treatment of childhood hereditary angioedema. Ann. Allergy Asthma Immunol. 92: 377, 2004.
19. Fenichel, G. M., Griggs, R. C., Kissel, J., et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 56: 1075, 2001.
20. Demling, R. H., and DeSanti, L. Oxandrolone induced lean mass gain during recovery from severe burns is maintained after discontinuation of the anabolic steroid. Burns 29: 793, 2003.
21. Hart, D. W., Wolf, S. E., Ramzy, P. I., et al. Anabolic effects of oxandrolone after severe burn. Ann. Surg. 233: 556, 2001.
22. Demling, R. H., and DeSanti, L. The rate of restoration of body weight after burn injury, using the anabolic agent oxandrolone, is not age dependent. Burns 17: 46, 2001.
23. Demling, R. H., and Orgill, D. P. The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J. Crit. Care 15: 12, 2000.
24. Barrow, R. E., Dasu, M. R. K., Ferrando, A. A., et al. Gene expression patterns in skeletal muscle of thermally injured children treated with oxandrolone. Ann. Surg. 237: 422, 2003.
25. Ishak, K. G., and Zimmerman, H. J. Hepatotoxic effects of the anabolic androgenic steroids. Semin. Liver Dis. 7: 230, 1987.
26. Shahidi, N. T. A review of the chemistry, biological action, and clinical applications of anabolic androgenic steroids. Clin. Ther. 23: 1355, 2001.
27. Dickerman, R. D., Pertusi, R. M., Zachariah, N. Y., et al. Anabolic steroid-induced hepatotoxicity: Is it overstated? Clin. J. Sport Med. 9: 34, 1999.
28. Parssinen, M., and Seppala, T. Steroid use and long term health risks in former athletes. Sports Med. 32: 83, 2002.
29. Morton, R., Gleason, O., and Yates, W. Psychiatric effects of anabolic steroids after burn injuries. Psychosomatics 41: 66, 2000.